Citi analyst Yigal Nochomovitz downgraded Apellis (APLS) to Neutral from Buy with a price target of $41, down from $44, after the company agreed to be acquired by Biogen (BIIB). The CVR triggers seem “aspirational” and would require significant inflection driven by the pre-filled syringe, the analyst says.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!
- Apellis downgraded to Hold from Buy at Jefferies
- Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal
- Apellis price target raised to $41 from $25 at Morgan Stanley
- Apellis downgraded to Market Perform from Outperform at William Blair